@article{RahimiBhalaKamphuisenetal.2012,
  author    = {Rahimi, Kazem and Bhala, Neeraj and Kamphuisen, Pieter and Emberson, Jonathan and Biere-Rafi, Sara and Krane, Vera and Robertson, Michele and Wikstrand, John and McMurray, John},
  title     = {Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials},
  series = {PLoS Medicine},
  volume    = {9},
  journal   = {PLoS Medicine},
  number    = {9},
  doi       = {10.1371/journal.pmed.1001310},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134279},
  pages     = {e1001310},
  year      = {2012},
  abstract  = {Background: It has been suggested that statins substantially reduce the risk of venous thromboembolic events. We sought to test this hypothesis by performing a meta-analysis of both published and unpublished results from randomised trials of statins. Methods and Findings: We searched MEDLINE, EMBASE, and Cochrane CENTRAL up to March 2012 for randomised controlled trials comparing statin with no statin, or comparing high dose versus standard dose statin, with 100 or more randomised participants and at least 6 months' follow-up. Investigators were contacted for unpublished information about venous thromboembolic events during follow-up. Twenty-two trials of statin versus control (105,759 participants) and seven trials of an intensive versus a standard dose statin regimen (40,594 participants) were included. In trials of statin versus control, allocation to statin therapy did not significantly reduce the risk of venous thromboembolic events (465 [0.9\%] statin versus 521 [1.0\%] control, odds ratio [OR] = 0.89, 95\% CI 0.78-1.01, p = 0.08) with no evidence of heterogeneity between effects on deep vein thrombosis (266 versus 311, OR 0.85, 95\% CI 0.72-1.01) and effects on pulmonary embolism (205 versus 222, OR 0.92, 95\% CI 0.76-1.12). Exclusion of the trial result that provided the motivation for our meta-analysis (JUPITER) had little impact on the findings for venous thromboembolic events (431 [0.9\%] versus 461 [1.0\%], OR = 0.93 [95\% CI 0.82-1.07], p = 0.32 among the other 21 trials). There was no evidence that higher dose statin therapy reduced the risk of venous thromboembolic events compared with standard dose statin therapy (198 [1.0\%] versus 202 [1.0\%], OR = 0.98, 95\% CI 0.80-1.20, p = 0.87). Risk of bias overall was small but a certain degree of effect underestimation due to random error cannot be ruled out. Conclusions: The findings from this meta-analysis do not support the previous suggestion of a large protective effect of statins (or higher dose statins) on venous thromboembolic events. However, a more moderate reduction in risk up to about one-fifth cannot be ruled out. Please see later in the article for the Editors' Summary.},
  language  = {en}
}
@article{NessBleySchmidtetal.2013,
  author    = {Ness, Thomas and Bley, Thorsten A. and Schmidt, Wolfgang A. and Lamprecht, Peter},
  title     = {The Diagnosis and Treatment of Giant Cell Arteritis},
  series = {Deutsches {\"A}rzteblatt International},
  volume    = {110},
  journal   = {Deutsches {\"A}rzteblatt International},
  number    = {21},
  doi       = {10.3238/arztebl.2013.0376},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-131676},
  pages     = {376-86},
  year      = {2013},
  abstract  = {Background: Giant cell arteritis (GCA) is the most common systemic vasculitis in persons aged 50 and above (incidence, 3.5 per 100 000 per year). It affects cranial arteries, the aorta, and arteries elsewhere in the body, e.g., in the limbs. Methods: We selectively review the pertinent literature, including guidelines and recommendations from Germany and abroad. Results: The typical symptoms of new-onset GCA are bi-temporal headaches, jaw claudiacation, scalp tenderness, visual disturbances, systemic symptoms such as fever and weight loss, and polymyalgia. The diagnostic assessment comprises laboratory testing (erythrocyte sedimentation rate, C-reactive protein), imaging studies (duplex sonography, high-resolution magnetic resonance imaging, positron-emission tomography), and temporal artery biopsy. The standard treatment is with corticosteroids (adverse effects: diabetes mellitus, osteoporosis, cataract, arterial hypertension). A meta-analysis of three randomized controlled trials led to a recommendation for treatment with methotrexate to lower the recurrence rate and spare steroids. Patients for whom methotrexate is contraindicated or who cannot tolerate the drug can be treated with azathioprine instead. Conclusion: Giant cell arteritis, if untreated, progresses to involve the aorta and its collateral branches, leading to various complications. Late diagnosis and treatment can have serious consequences, including irreversible loss of visual function.},
  language  = {en}
}
@article{KohlGruendlerHuysetal.2015,
  author    = {Kohl, S. and Gruendler, T. O. J. and Huys, D. and Sildatke, E. and Dembek, T. A. and Hellmich, M. and Vorderwulbecke, M. and Timmermann, L. and Ahmari, S. E. and Klosterkoetter, J. and Jessen, F. and Sturm, V. and Visser-Vandewalle, V. and Kuhn, J.},
  title     = {Effects of deep brain stimulation on prepulse inhibition in obsessive-compulsive disorder},
  series = {Translational Psychiatry},
  volume    = {5},
  journal   = {Translational Psychiatry},
  number    = {e675},
  doi       = {10.1038/tp.2015.171},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-138300},
  year      = {2015},
  abstract  = {Owing to a high response rate, deep brain stimulation (DBS) of the ventral striatal area has been approved for treatment-refractory obsessive-compulsive disorder (tr-OCD). Many basic issues regarding DBS for tr-OCD are still not understood, in particular, the mechanisms of action and the origin of side effects. We measured prepulse inhibition (PPI) in treatment-refractory OCD patients undergoing DBS of the nucleus accumbens (NAcc) and matched controls. As PPI has been used in animal DBS studies, it is highly suitable for translational research. Eight patients receiving DBS, eight patients with pharmacological treatment and eight age-matched healthy controls participated in our study. PPI was measured twice in the DBS group: one session with the stimulator switched on and one session with the stimulator switched off. OCD patients in the pharmacologic group took part in a single session. Controls were tested twice, to ensure stability of data. Statistical analysis revealed significant differences between controls and (1) patients with pharmacological treatment and (2) OCD DBS patients when the stimulation was switched off. Switching the stimulator on led to an increase in PPI at a stimulus-onset asynchrony of 200 ms. There was no significant difference in PPI between OCD patients being stimulated and the control group. This study shows that NAcc-DBS leads to an increase in PPI in tr-OCD patients towards a level seen in healthy controls. Assuming that PPI impairments partially reflect the neurobiological substrates of OCD, our results show that DBS of the NAcc may improve sensorimotor gating via correction of dysfunctional neural substrates. Bearing in mind that PPI is based on a complex and multilayered network, our data confirm that DBS most likely takes effect via network modulation.},
  language  = {en}
}